Table 1.
Baseline patient demographics.
| Variable | Fluconazole | Posaconazole | Voriconazole |
|---|---|---|---|
| Sample size | 21 | 4 | 3 |
| Age in years, median (range) | 47 (24–58) | 50 (32–61) | 21 (20–65) |
| Sex, number (%) | |||
| Male | 13 (61.9) | 2 (50.0) | 1 (33.3) |
| Female | 8 (38.1) | 2 (50.0) | 2 (66.7) |
| Race, number (%) | |||
| Caucasian | 13 (61.9) | 3 (75.0) | 2 (66.7) |
| Hispanic | 5 (23.8) | 1 (25.0) | – |
| Asian | 1 (4.8) | – | 1 (33.3) |
| Unknown | 2 (9.5) | – | – |
| Hematologic malignancy, number (%) | |||
| Acute lymphoblastic leukemia | 4 (19.0) | – | 1 (33.3) |
| Acute myeloid leukemia | 9 (42.9) | 2 (50.0) | 1 (33.3) |
| Chronic myeloid leukemia | 1 (4.8) | 1 (25.0) | – |
| Non-Hodgkin lymphoma | 2 (9.5) | – | – |
| Hodgkin lymphoma | 3 (14.3) | – | – |
| Myelofibrosis | 2 (9.5) | 1 (25.0) | – |
| Myelodysplastic syndrome | – | – | 1 (33.3) |
| Stem-cell donor type, number (%) | |||
| Matched unrelated | 3 (14.3) | 1 (25.0) | 2 (66.7) |
| Matched related | 15 (71.4) | 3 (75.0) | 1 (33.3) |
| Mismatched unrelated | 2 (9.5) | – | – |
| Mismatched related | 1 (4.8) | – | – |
| Renal function, mean ± SD | |||
| SCr on admission (mg/dL) | 0.9 ± 0.2 | 1.0 ± 0.2 | 0.8 ± 0.3 |
| SCr on discharge (mg/dL) | 1.0 ± 0.3 | 1.3 ± 0.3 | 1.6 ± 1.5 |
| SCr peak (mg/dL) | 1.1 ± 0.4 | 3.1 ± 3.1 | 1.6 ± 1.5 |
| Hepatic function, mean ± SD | |||
| ALT on admission (U/L) | 29 ± 24 | 29 ± 34 | 26 ± 17 |
| ALT on discharge (U/L) | 29 ± 25 | 24 ± 13 | 17 ± 6 |
| ALT peak (U/L) | 47 ± 35 | 38 ± 14 | 48 ± 43 |
| AST on admission (U/L) | 21 ± 12 | 20 ± 12 | 26 ± 13 |
| AST on discharge (U/L) | 30 17 | 30 20 | 21 4 |
| AST peak (U/L) | 43 ± 22 | 44 ± 14 | 49 ± 27 |
| Length of stay post-transplant, mean ± SD | 25 ± 5 | 17 ± 3 | 32 ± 21 |